Avacta Group has completed a placing and subscription
November 2019 — Avacta Group Plc has raised US$11.3 million to continue developing next generation cancer therapies.
Avacta’s mission is to shape the future of medicine by developing safe and efficacious drugs and powerful research and diagnostic tools. Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumor targeted chemotherapy. With this approach, the company aims to address the lack of a durable response to current immunotherapies experienced by most patients.
Our role in the transaction
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker, assisting Avacta’s management team and shareholders all the way from the start to the successful completion of the fundraising. During this process the team initiated and advised on many aspects, including, among others, securing pre-commitments from both existing and new institutional investors, deal structuring, document preparation and the fundraise pricing and sizing.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn more